Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN: ONO-5334 in Postmenopausal Osteoporosis or Osteopenia
NCT00532337Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2007
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ONO-5334 in osteoporosis and osteopenia (5 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Mean bone mineral density of the lumbar spine (L1-4) at 12 months. Started Oct 2007; status: completed.
02
Drugs
ONO-5334
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on NCT00532337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532337.